A regulatory non-interventional study to monitor the safety and efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean patients with Chronic Kidney Disease (CKD)

First published 24/10/2023

Last updated 05/02/2025

EU PAS number:

EUPAS107293

Study

Ongoing

Documents

Study protocol

Initial protocol

[Eng]1245-0323-onis-protocol-final-v2-EUPAS.pdf

English (654.31 KB - PDF)View document

Updated protocol

1245-0323-protocol-v3-final_Redacted.pdf

First published: 04/02/2025

English (1021.66 KB - PDF)View document

Study results

Study report

Other information

Secondary tabs